Navigation Links
Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy

Hicksville and Hauppauge, NY (PRWEB) July 14, 2014

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Ozurdex, a corticosteroid manufactured by Allergan, recently obtained an additional FDA-approved indication for use in diabetic macular edema. Ozurdex was previously approved by the FDA in 2009 for treatment of retinal vascular occlusions and and in 2010 for non-infectious uveitis (inflammation in the eye).

DME, a leading cause of vision loss in diabetic patients, is a condition in which microvascular damage from diabetes leads to leakage in the central portion of the retina, the macula. This causes blurring and loss of vision, and eventually legal blindness. The OZURDEX® biodegradable implant is delivered as an injection, and is administered during an office visit. The medication is slowly released over a period of months, suppressing inflammation, a key factor in DME. On average, patients receiving the medication demonstrate an improvement in vision and less leakage.

According to James M. Maisel, M.D., Chairman of the Retina Group of New York and a vitreoretinal surgeon, “Laser treatments and vitreous surgery have nearly eliminated the blinding complications of proliferative diabetic retinopathy for decades. However, over half a million diabetics with the background form of diabetic retinopathy develop diabetic macular edema (DME), threatening their fine vision, and their ability to read and drive. Precise focal laser treatment for DME typically only slowed visual loss. In 2010, Lucentis® was approved for treatment of DME and quickly became the standard of care, stabilizing or improving vision two lines in two years in about 1/3 of patients but often requiring monthly injections. We are thrilled to now have a second FDA-approved medication, Ozurdex, for treatment of DME,” Dr. Maisel continues. “The mechanism of action is different from Lucentis and it may act in concert for challenging cases with duration of action of up to six months.”

Rodney P. Coe, M.D., an associate retinal specialist with the Retina Group of New York, states that, “Our group has over 5 years of experience administering Ozurdex for treatment of posterior uveitis and retinal vascular occlusions. Ozurdex is administered in the eye during routine office visits and has proven to be safe and effective. Diabetic macular edema involves complex mechanisms, and having an additional treatment option broadens our ability to control this condition.”

For more information about Ozurdex treatment for DME, or to schedule a consultation with the Retina Group of New York, please call 516.939.6100 or 631-273-1818. An NIH video, "Diabetic Retinopathy" can be viewed on YouTube.

About The Retina Group of New York
The Retina Group of New York is composed of Board Certified Ophthalmologists with additional subspecialty training in vitreous and retinal surgery and medical retinal diagnosis and treatment. The group provides eye care for patients with retinal problems such as diabetic retinopathy, macular degeneration, retinal vascular disease, retinal detachments, vitreoretinal interface disorders such as VMA, macular puckers and holes, surgical complications, uveitis and second opinions. Members of the group holds staff privileges at seven area hospitals, teaching appointments and served as a Corporate Advisory Board member for the Foundation of the American Academy of Ophthalmology (AAO), the Juvenile Diabetes Foundation Medical Advisory Board and the AAO Instrument and Device and Low Vision Committees. They have received research grants from the U.S. Public Health Service and the National Institute of Health and represented the National Society to Prevent Blindness at the ANSI Z-80 committee helping to establish many ophthalmic industry standards.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Antibiotics Linked to Retinal Detachment Risk
2. Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease
3. New type of retinal prosthesis could better restore sight to blind, Stanford study says
4. Prosthetic retina offers simple solution to restoring sight
5. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
6. Retinal Device Restores Sight to Blind Mice
7. Retina Specialty Institute Gives Patients Something to Look Forward to in Crestview
8. UCIs Gavin Herbert Eye Institute receives $3 million for retinal degeneration research
9. San Antonio Eye Center Welcomes Retina Specialist Dr. Calvin Christopher Brown
10. Nationally-Recognized Retinal Expert Returns to Gainesville, Joins Retina Specialty Institute
11. Preferred retinal location may aid rehabilitation in patients with central vision loss
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... the United States, today announced the release of its limited edition holiday seasonal ... Cocktail Agua Fresca. All feature the unique flavor combinations and delicious taste Califia ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ProText Kinetic Panel ... . With ProText Kinetic Panel, users can create energetic text animations in any layout ... into the Final Cut Pro X timeline and stylize the text. With intuitive on-screen ...
(Date:10/13/2015)... , ... October 13, 2015 , ... In an age ... costs were 36 percent lower per square foot than in 2009. The Williamsport Regional ... of heating and cooling has decreased by eight percent. , According to Facilities ...
(Date:10/13/2015)... York, NY (PRWEB) , ... October 13, 2015 , ... ... The app helps individuals find others to train with, participate in local fitness ... App Store and Google Play. , “As high medical costs drive us to get ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, Inc., the ... of Synergy 2015. The annual WennSoft KEY2ACT user conference will take place from ... unite customers, partners, WennSoft team members and sponsors to facilitate the sharing of ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015 WuXi PharmaTech ... and technology platform company serving the pharmaceutical, biotechnology, ... has launched a mobile version of OncoWuXi, the ... to access oncology models and data on the ... and at any time to identify relevant tumor ...
(Date:10/13/2015)... 13, 2015 Health Gorilla ( ) today ... – a secure platform for clinical data and communications ... about and manage healthcare in the US. The launch follows ... a combined total of $4.4M raised to date, with ... True Ventures , Harris Barton , Orfin Ventures ...
(Date:10/13/2015)... DUBLIN , Oct. 8, 2015 Research ... of the "World Anti-counterfeit Pharmaceuticals and Cosmetics Packaging ... report to their offering. --> ... packaging market to grow at a CAGR of 15.7% ... The hologram authentication technology segment accounted for about ...
Breaking Medicine Technology: